Informed Prostate Cancer Patient Support

  RadioCode 102 on Amazon $249 Consumer Radiation Detectors to Prove Safety to Your Family BLUF (Bottom Line Up Front) Men taking Pluvicto have experienced unfounded and excessive concern and isolation from their family over radiation hazard. Objective measurement will convince your family far more effectively than scientific papers. Several consumer-grade radiation detectors ($100-400) can measure radiation from Lu-177 Pluvicto and demonstrate in real-time that you're emitting nothing above background levels after 7-10 days. This article provides specific product recommendations, validation data on their accuracy for Lu-177 detection, practical usage protocols, and exactly how to present the data to your family to end the unnecessary month-long isolation. Why Measurement Will Work When Evidence Hasn't W. Edwards Deming was absolutely right. Your family doesn't need more papers and general guidelines —they need concrete, visible proof. Let's make that happen. The P...

Single Midlife PSA Test May Identity Long-Term Prostate Cancer Risk | MedPage Today New Evidence Supports Risk-Stratified Screening BLUF (Bottom Line Up Front): A major German study published February 3, 2026, found that men with a PSA below 1.0 ng/mL at midlife face very low prostate cancer risk for the next 20 years—just 3.3% cumulative incidence—suggesting these men could safely reduce screening frequency and avoid unnecessary biopsies. Combined with 23-year follow-up data from Europe's largest screening trial showing a 13% mortality reduction, new FDA-approved blood tests, and updated guidelines for high-risk populations including Black men, the evidence increasingly supports personalized, risk-based screening strategies that maximize early detection benefits while minimizing overdiagnosis harms. A Breakthrough in Risk Stratification For decades, prostate cancer screening has been caught in a dilemma: PSA testing saves lives by detecting cancer early, but it also leads to...

Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI | Prostate Cancer and Prostatic Diseases BLUF (Bottom Line Up Front) Chinese researchers have successfully performed prostate cancer surgery on 120 men without prior biopsy, using advanced imaging alone to diagnose cancer. Published January 31, 2026, in Prostate Cancer and Prostatic Diseases , this study achieved 100% accuracy in detecting clinically significant cancer using a careful algorithm combining PSMA PET/CT and multiparametric MRI scans. While this radical departure from standard practice shows promise for carefully selected patients, it remains experimental and requires independent validation before becoming routine care. The Traditional Path—And Its Problems For decades, prostate biopsy has been the gold standard for diagnosing prostate cancer. A urologist inserts a needle through the rectal wall 10-12 times to collect tissue samples, guided by ultrasound. The procedu...

Reprogramming Aggressive Prostate Cancer to Enable Immune mediated Tumor Elimination - Paul Mathew - YouTube Breaking the Cold Tumor Barrier: New Bispecific Antibody Targets Hidden Enemy in Prostate Cancer BLUF (Bottom Line Up Front): Researchers at Tufts Medical Center have developed a novel bispecific antibody that could transform prostate cancer treatment by targeting aggressive "basal-type" cancer cells that evade the immune system, resist hormone therapy, and drive bone metastases. By simultaneously blocking two integrin proteins (alpha-5 and alpha-V), the antibody disrupts the mechanical signaling that allows cancer cells to hide from immune surveillance, potentially making prostate cancer responsive to immunotherapy for the first time. The treatment is being prepared for first-in-human clinical trials within the next year through spinout company Jolian Therapeutics. The Hidden Architecture of Aggressive Prostate Cancer For over two decades, Dr. Paul Mathew at Tufts...